PL3207941T3 - Sposoby i kompozycje oparte na koniugacie ludzkiej interleukiny (IL)-3 z toksyną błoniczą - Google Patents

Sposoby i kompozycje oparte na koniugacie ludzkiej interleukiny (IL)-3 z toksyną błoniczą

Info

Publication number
PL3207941T3
PL3207941T3 PL17151480T PL17151480T PL3207941T3 PL 3207941 T3 PL3207941 T3 PL 3207941T3 PL 17151480 T PL17151480 T PL 17151480T PL 17151480 T PL17151480 T PL 17151480T PL 3207941 T3 PL3207941 T3 PL 3207941T3
Authority
PL
Poland
Prior art keywords
conjugates
interleukin
methods
diphtheria toxin
compositions based
Prior art date
Application number
PL17151480T
Other languages
English (en)
Other versions
PL3207941T6 (pl
Inventor
Arthur E. Frankel
Original Assignee
Scott & White Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott & White Memorial Hospital filed Critical Scott & White Memorial Hospital
Publication of PL3207941T3 publication Critical patent/PL3207941T3/pl
Publication of PL3207941T6 publication Critical patent/PL3207941T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17151480T 2006-09-07 2007-09-07 Sposoby i kompozycje oparte na koniugacie ludzkiej interleukiny (IL)-3 z toksyną błoniczą PL3207941T6 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84347106P 2006-09-07 2006-09-07
US93277207P 2007-06-01 2007-06-01
EP17151480.5A EP3207941B3 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
EP07837840.3A EP2063907B1 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
PCT/US2007/019481 WO2008030539A2 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Publications (2)

Publication Number Publication Date
PL3207941T3 true PL3207941T3 (pl) 2020-07-27
PL3207941T6 PL3207941T6 (pl) 2020-11-16

Family

ID=39157851

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17151480T PL3207941T6 (pl) 2006-09-07 2007-09-07 Sposoby i kompozycje oparte na koniugacie ludzkiej interleukiny (IL)-3 z toksyną błoniczą
PL07837840T PL2063907T3 (pl) 2006-09-07 2007-09-07 Sposoby i kompozycje oparte na koniugatach toksyny błoniczej z interleukiną-3

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07837840T PL2063907T3 (pl) 2006-09-07 2007-09-07 Sposoby i kompozycje oparte na koniugatach toksyny błoniczej z interleukiną-3

Country Status (17)

Country Link
US (7) US7763242B2 (pl)
EP (4) EP2063907B1 (pl)
JP (7) JP5550905B2 (pl)
AU (1) AU2007293047B2 (pl)
CA (5) CA2923381A1 (pl)
CY (3) CY1119654T1 (pl)
DK (2) DK3207941T6 (pl)
ES (3) ES2646545T3 (pl)
FR (1) FR21C1017I2 (pl)
HU (2) HUE048356T2 (pl)
LT (2) LT3207941T (pl)
LU (1) LUC00206I2 (pl)
NL (1) NL301103I2 (pl)
PL (2) PL3207941T6 (pl)
PT (1) PT3207941T (pl)
SI (1) SI3207941T1 (pl)
WO (1) WO2008030539A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
JP5550905B2 (ja) 2006-09-07 2014-07-16 スコット アンド ホワイト ヘルスケア ジフテリア毒素−インターロイキン−３コンジュゲートに基づく方法及び組成物
WO2010027802A2 (en) 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
JP6018507B2 (ja) * 2010-02-17 2016-11-02 シーエスエル、リミテッド Ｉ型インターフェロン産生細胞を標的化するための組成物及び方法
WO2011160082A2 (en) 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
AU2011338425A1 (en) 2010-12-08 2013-05-02 Stemcentrx, Inc. Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP3093294A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use
PE20150091A1 (es) 2012-02-24 2015-02-16 Stem Centrx Inc Anticuerpos anti-sez6 y metodos de empleo
SMT201900339T1 (it) 2013-02-22 2019-07-11 Medimmune Ltd Coniugati anticorpo anti-dll3/pbd e loro usi
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
DK3052102T3 (da) * 2013-10-04 2020-03-09 Aptose Biosciences Inc Sammensætninger til behandling af cancere
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
MX2016007369A (es) 2013-12-12 2016-09-08 Stemcentrx Inc Nuevos anticuerpos anti-dpep3 y metodos de uso.
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
EP3711780A3 (en) 2014-04-30 2020-12-09 Pfizer Inc Anti-ptk7 antibody-drug conjugates
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
AU2017254674A1 (en) 2016-04-21 2018-11-01 Abbvie Stemcentrx Llc Novel anti-BMPR1B antibodies and methods of use
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
EP3784270A1 (en) 2018-04-27 2021-03-03 Stemline Therapeutics Inc. Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3)
EP3802834A4 (en) * 2018-05-30 2022-08-03 The Governing Council of the University of Toronto METHODS AND KITS FOR IDENTIFYING A PROTEIN RELATED TO RECEPTOR-LIGAND INTERACTIONS
CN113329752A (zh) 2018-10-31 2021-08-31 斯坦林治疗公司 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法
WO2020112642A1 (en) 2018-11-30 2020-06-04 Stemline Therapeutics, Inc. Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
EP4061967A1 (en) * 2019-11-21 2022-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml)
CA3204584A1 (en) 2020-12-10 2022-06-16 Stemline Therapeutics, Inc. Improved lyophilized formulation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003971A1 (en) 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
GB8628068D0 (en) 1986-11-24 1986-12-31 Unilever Plc Aqueous gel comprising carrageenan
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
EP0517829B2 (en) 1990-03-02 2007-12-26 Boston Medical Center Corporation Improved chimeric toxins
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4140121C2 (de) 1991-12-05 1994-06-30 Manfred Mueller Verfahren zum Herstellen von gefaßten, gegossenen Schmuckstücken
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
AU5965296A (en) * 1995-05-31 1996-12-18 Regents Of The University Of Minnesota Recombinant polypeptide cytotoxins for cancer treatment
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
CA2393132A1 (en) 1999-12-03 2001-06-07 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
AU2001250030B2 (en) 2000-03-06 2004-11-25 University Of Kentucky Research Foundation Use of a compound that selectively binds to CD123 to impair hematologic cancer progenitor cell
WO2002070007A1 (en) 2001-03-02 2002-09-12 Medimmune, Inc. Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
AU2002322478A1 (en) 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
JP5550905B2 (ja) * 2006-09-07 2014-07-16 スコット アンド ホワイト ヘルスケア ジフテリア毒素−インターロイキン−３コンジュゲートに基づく方法及び組成物
AU2014201901B2 (en) 2006-09-07 2016-05-05 Scott & White Healthcare Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
FR2982762B1 (fr) 2011-11-21 2014-12-12 Patrick Arnoux Appareil de brossage de dents a multiples systemes rotatifs de brossage
CN104245720A (zh) 2012-02-29 2014-12-24 Ambrx公司 白细胞介素-3多肽结合物和其用途
WO2021044497A1 (ja) 2019-09-02 2021-03-11 日本電信電話株式会社 データ分析処理装置、データ分析処理方法及びデータ分析処理プログラム

Also Published As

Publication number Publication date
US20190169251A1 (en) 2019-06-06
US9631006B2 (en) 2017-04-25
CA2698595A1 (en) 2008-03-13
EP3520806A1 (en) 2019-08-07
EP2063907A2 (en) 2009-06-03
CY1123035T1 (el) 2021-09-14
LTC3207941I2 (pl) 2022-10-10
CA3053981A1 (en) 2008-03-13
PL2063907T3 (pl) 2018-06-29
WO2008030539A2 (en) 2008-03-13
EP3520806B1 (en) 2024-03-20
US20130315860A1 (en) 2013-11-28
LUC00206I2 (pl) 2022-10-07
DK3207941T6 (da) 2020-11-09
CA3007075C (en) 2019-10-15
EP2063907A4 (en) 2011-08-31
ES2781402T3 (es) 2020-09-01
LTPA2021507I1 (pl) 2021-06-10
WO2008030539A3 (en) 2009-04-09
US10259853B2 (en) 2019-04-16
US20160024167A1 (en) 2016-01-28
DK2063907T3 (da) 2017-11-13
ES2987072T3 (es) 2024-11-13
EP3207941B1 (en) 2019-12-25
CA2923381A1 (en) 2008-03-13
ES2646545T3 (es) 2017-12-14
CY1119654T1 (el) 2019-07-10
JP2016155830A (ja) 2016-09-01
EP3207941A1 (en) 2017-08-23
US9181317B2 (en) 2015-11-10
JP6336500B2 (ja) 2018-06-06
CY2021011I1 (el) 2021-10-15
JP2010502712A (ja) 2010-01-28
CA2698595C (en) 2016-07-26
FR21C1017I1 (pl) 2021-07-02
HUE048356T2 (hu) 2020-07-28
JP5902223B2 (ja) 2016-04-13
CA3053981C (en) 2022-07-12
EP4414036A3 (en) 2024-10-09
NL301103I2 (nl) 2021-08-02
JP2022065089A (ja) 2022-04-26
HUS2100013I1 (hu) 2021-05-28
JP2018135378A (ja) 2018-08-30
US8470307B2 (en) 2013-06-25
EP2063907B1 (en) 2017-08-09
US20080138313A1 (en) 2008-06-12
EP3207941B3 (en) 2020-08-19
EP4414036A2 (en) 2024-08-14
DK3207941T3 (da) 2020-03-30
CY2021011I2 (el) 2021-10-15
US11130792B2 (en) 2021-09-28
CA3153438A1 (en) 2008-03-13
US20220235108A1 (en) 2022-07-28
JP2014144967A (ja) 2014-08-14
JP2020079260A (ja) 2020-05-28
ES2781402T7 (es) 2021-06-09
JP5550905B2 (ja) 2014-07-16
LT3207941T (lt) 2020-04-10
PT3207941T (pt) 2020-04-02
JP6654660B2 (ja) 2020-02-26
US20180022788A1 (en) 2018-01-25
PL3207941T6 (pl) 2020-11-16
FR21C1017I2 (fr) 2022-04-22
SI3207941T1 (sl) 2020-08-31
NL301103I1 (nl) 2021-06-17
US20090232767A1 (en) 2009-09-17
JP2024088720A (ja) 2024-07-02
US7763242B2 (en) 2010-07-27
AU2007293047A1 (en) 2008-03-13
CA3007075A1 (en) 2008-03-13
AU2007293047B2 (en) 2014-01-09
US12180257B2 (en) 2024-12-31
CA3153438C (en) 2024-03-12

Similar Documents

Publication Publication Date Title
HUS2100013I1 (hu) Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények
EP2182922A4 (en) ANTIGEN-ADJUVANS COMPOSITIONS AND METHOD
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
ZA201203709B (en) Immunogenic compositions and methods
EP2041175A4 (en) TARGETED IMMUNOJUGATE
LT1988910T (lt) Akriloiloksietilfosforilcholiną turintys polimero konjugatai ir jų gavimo būdas
IL227934A0 (en) Immunogenic preparation
IL193922A0 (en) Anti-tat226 antibodies and immunoconjugates
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
ZA201001206B (en) Saccharide-containing protein conjugates and uses thereof
ZA200902161B (en) Antiobodies and immunoconjugates and uses therefor
EP2370472A4 (en) LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
GB0721291D0 (en) Methods and compositions
IL195561A0 (en) Methods and compositions for targeting hepsin
GB0719526D0 (en) Compositions and methods
IL199718A0 (en) Peptide-complement conjugates
GB0617171D0 (en) Novel compositions and methods
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0606416D0 (en) Immunogenic composition
GB0501348D0 (en) Compositions and methods
GB0602688D0 (en) Conjugates
GB0625230D0 (en) Compositions and methods
GB0616269D0 (en) Methods and compositions
GB0607565D0 (en) Methods and compositions
SG10201403055VA (en) Conjugation methods